Body Protective Compound 157 is a synthetic 15-amino-acid peptide derived from a cytoprotective protein in human gastric juice. It is the most studied non-approved tissue-repair research peptide, with a substantial preclinical literature and no completed human clinical trials.
Research and educational reference only. Not medical advice, dosing guidance, or an offer for sale.
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain (sequence: GEPPPGKPADDAGLV) derived from a protective protein (BPC) isolated from human gastric juice. It is not a fragment of any approved drug; it has no endogenous equivalent circulating in the body at pharmacological concentrations.
The compound entered the research literature primarily through work from a Croatian laboratory in the 1990s–2000s and has since generated a substantial body of rodent experiments across multiple tissue contexts. Its short sequence makes it inexpensive to synthesize, which partly explains its outsized presence in the non-approved research-peptide literature: accessible cost lowers the barrier for preclinical investigation.
It is not approved by the FDA or any major regulatory agency for any indication. It is prohibited by the World Anti-Doping Agency (WADA). Its status in the compounding pharmacy context has been contested.
None fully established in humans; based on cell culture and rodent experiments
VEGFR2 upregulation
Proposed to upregulate vascular endothelial growth factor receptor 2 (VEGFR2), promoting new-vessel formation and tissue vascularisation in wound models.
Nitric oxide (NO) pathway
Studies suggest modulation of endothelial nitric-oxide synthase (eNOS), with downstream effects on blood flow and cytoprotection.
Growth-factor pathway interactions
Reported interactions with PDGF, EGF, and GH-receptor signaling in cell models — contributing to fibroblast activation and ECM remodeling.
All completed studies are in cell or animal models
| Research context | Model | Reported finding | Evidence level |
|---|---|---|---|
| Tendon & ligament repair | Rodent (transection, crush) | Accelerated histological repair, tensile strength improvement | Preclinical |
| Gastrointestinal protection | Rodent ulcer & IBD models | Reduced ulcer area, mucosal cytoprotection | Preclinical |
| Muscle repair | Rodent crush & ischemia | Reduced fibrosis, improved strength recovery | Preclinical |
| Angiogenesis | Cell culture / rodent | VEGFR2 upregulation, new-vessel formation markers | Preclinical |
| Human clinical evidence | — | No controlled human trials completed | None |
Two distinct peptides frequently studied in overlapping contexts — different sequences, different mechanisms
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Source | Derived from human gastric juice protein | Active fragment of thymosin β4 |
| Sequence length | 15 amino acids | 7 amino acids |
| Primary mechanism | VEGFR2 / NO / growth-factor pathways | G-actin sequestration; cytoskeletal remodeling |
| Main research contexts | Tendon, GI, muscle | Wound healing, cardiac, hair follicle |
| Sport status | WADA-prohibited (S2 peptide hormones) | WADA-prohibited (S2) |
| FDA approval | None | None |
| Evidence level | Preclinical only | Preclinical only |
The two compounds are often compared because they appear in overlapping tissue-repair research contexts, but their sequences, targets, and proposed mechanisms are unrelated.
BPC-157’s 15-residue length places it at the short end of research peptides, making synthesis comparatively inexpensive. That accessibility is part of its appeal for preclinical researchers — but it is also precisely why the market carries a high proportion of low-quality material.
Short peptides require fewer coupling cycles but are not inherently pure. Common quality failures include truncation sequences (incomplete assembly), oxidation at methionine (if present in related analogs), and outright adulteration with filler. The only reliable quality check is a batch-specific certificate of analysis with identity confirmation by mass spectrometry and purity by reversed-phase HPLC — not an aggregate COA, not a manufacturer’s certificate applied to multiple lots.
How research peptides are synthesized and characterizedWhether a licensed compounding pharmacy may legally prepare these substances — a separate question from FDA drug approval
The regulatory position of these peptides changed materially in 2026, and it changed in a direction most summaries overstate. BPC-157 spent nearly three years on the list of bulk substances FDA considers a significant safety risk. It came off that list in April 2026, and an FDA advisory committee narrowly recommended it for compounding that July. Neither step makes it a legal compounded preparation today, and neither makes it an approved drug.
Added to Category 2 in September 2023 and removed on April 22, 2026. PCAC then voted 8–6, with one abstention, to recommend it for the 503A bulks list. The vote does not authorize compounding.
Nominated as the thymosin β4 fragment LKKTETQ. Removed from Category 2 on April 22, 2026; recommended by PCAC on the same 8–6 vote as BPC-157 and KPV.
Removed from Category 2 on April 22, 2026 and recommended by PCAC 8–6, with one abstention, on July 23, 2026.
Injectable GHK-Cu was placed in Category 2 in September 2023 and removed on April 22, 2026. It was not among the peptides reviewed at the July 2026 PCAC meeting. Topical cosmetic use is a separate regulatory question entirely.
None of these statuses is FDA approval, and none establishes efficacy, dosing, or a benefit-risk profile. Legal 503A compounding requires FDA to place a substance on the bulks list through notice-and-comment rulemaking. That step had not been completed for any peptide on this page as of the review date.
Regulatory status reviewed
Side-by-side pages covering BPC-157 and the peptides it is most often confused with
BPC-157 vs TB-500
two repair peptides, two different mechanisms
GHK-Cu vs AHK-Cu
same copper chemistry, different target tissue
BPC-157 vs GHK-Cu
systemic repair versus skin & matrix remodeling
TB-500 vs GHK-Cu
move the cells versus remodel the matrix
What is BPC-157?
BPC-157 (Body Protective Compound 157) is a synthetic 15-amino-acid peptide derived from a cytoprotective protein identified in human gastric juice. It is studied in preclinical models — primarily rodent and cell-culture — for tissue repair, GI protection, and angiogenesis. It has no FDA-approved medical use.
What is the proposed mechanism of action for BPC-157?
Several mechanisms have been proposed, none fully established in humans. The most cited involve upregulation of the VEGFR2 receptor (promoting angiogenesis), modulation of endothelial nitric-oxide synthase (eNOS), and interactions with PDGF and EGF signaling pathways. These are based on cell-culture and rodent experiments; the operative mechanism in humans, if any, is unknown.
What tissues and conditions has BPC-157 been studied in?
Preclinical research contexts include tendon and ligament repair (transection and crush models), gastrointestinal protection (ulcer and IBD models), skeletal muscle repair, and angiogenesis. There are no completed, controlled human clinical trials.
How does BPC-157 differ from TB-500?
BPC-157 and TB-500 are completely distinct peptides with unrelated mechanisms. BPC-157 (15 residues) is studied primarily through VEGFR2/NO pathways. TB-500 (7 residues, derived from thymosin β4) works through G-actin sequestration and cytoskeletal remodeling. Both are preclinical and not FDA-approved; both are prohibited in regulated sport.
Is BPC-157 banned in sport?
Yes — BPC-157 is prohibited by the World Anti-Doping Agency (WADA) under category S2 (Peptide Hormones and Related Substances). This is regardless of whether human efficacy has been established.
Why does synthesis quality matter for BPC-157?
At only 15 residues, BPC-157 is inexpensive to synthesize, which makes it easy to produce low-quality or adulterated material. The low cost is precisely why a batch-specific certificate of analysis (COA) — with identity confirmation by mass spectrometry and purity by HPLC — is essential for any research-grade supply.
Did the FDA approve BPC-157 in 2026?
No. Two separate things happened, and neither is approval. In April 2026 FDA removed BPC-157 from Category 2, the list of bulk substances it had identified as presenting significant safety risks. In July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it to the 503A bulks list. That vote is not binding on FDA. Lawful compounding would still require FDA to place the substance on the bulks list through notice-and-comment rulemaking, which had not happened as of September 2026. Drug approval is a different process again, and BPC-157 has not entered it.
Are there completed human clinical trials of BPC-157?
No published, peer-reviewed randomised controlled trial has reported efficacy for any indication in humans. Early-phase safety work in inflammatory bowel disease has been referenced for years but is not available as a completed randomised trial with published results. The evidence base remains overwhelmingly preclinical, and the regulatory movement in 2026 did not change that — an advisory committee recommendation reflects a judgment about compounding access, not new efficacy data.
What does the evidence base for BPC-157 look like overall?
The evidence base is almost entirely preclinical. Studies span multiple tissue contexts and consistently report positive findings in rodent models — which has driven significant research interest — but no controlled human clinical trials have been completed. The translation from rodent to human remains unproven, and any use in humans is outside approved medical practice.